Access across borders: will cross-border collaboration initiatives harmonize or hinder progress?
As the EU HTA Regulation (EU HTAR) comes into force, attention is turning to how collaborative initiatives like the Joint Clinical Assessment (JCA), the Health Economics Methods Advisory (HEMA), and the Joint Nordic HTA Bodies (JNHB) might improve the efficiency and consistency of health technology assessments (HTA) across borders. These initiatives aim to streamline evidence generation, reduce duplicative efforts, and improve patient access to innovative therapies.
But is global HTA collaboration really an achievable goal?
This was the topic of an educational symposium at ISPOR 2025 which brought together leading experts in HTA to examine the early implementation of these initiatives and assess their long-term implications.
Titled, "Bringing us together or pushing us apart: Will JCA, HEMA, and other cross-border collaboration initiatives improve patient access?", the session was moderated by Erika Wissinger, PhD (Cencora) and featured Michael Drummond, MCom, DPhil (University of York), Jon Campbell, PhD (National Pharmaceutical Council), and Eldon Spackman, PhD (University of Calgary).
Sponsorship for this Deep Dive was provided by Cencora